If a reactive intermediate is produced faster than glutathione and other Phase II systems can neutralize it, oxidative stress and liver injury may increase
Patel, who is also the author of The Glutathione Revolution

Here's the appeal workflow that gets results: Pull the ERA or EOB and identify the exact CARC and RARC codes for the denial Match the CARC code to the denial table above to confirm the root cause Gather supporting documentation: Clinical notes showing injection administration Drug name, dose, route, and anatomical site Prescribing physician's order Prior authorization approval number, if applicable Correct the claim line if the denial stems from a billing error such as a missing modifier, wrong POS, or missing NDC Write the appeal letter citing the specific payer policy, CMS guideline, or NCCI rule that supports separate payment Submit the corrected claim or formal appeal within the payer's timely filing limit Track the appeal with an expected resolution date so it doesn't age out Per CMS appeals process guidance , documentation supporting the clinical necessity of the service is the most critical component of a successful appeal

Use / Stability Stable for at least 2 years after receipt when stored at -20C
Diagnosis [edit] The diagnosis is generally suspected when patients from certain ethnic groups (see epidemiology) develop anemia, jaundice, and symptoms of hemolysis after challenges from any of the above causes, especially when there is a positive family history